stemmacolore
Search

Clinical Trials

Clinical Trials

The intensive clinical activity of the IOV is carried out by hospital and university doctors who use cutting-edge treatment programs, with the most accredited conventional cancer treatments. This clinical activity is flanked and complemented by an equally lively research activity that leads to the acquisition of new knowledge for the progress of medicine and offers the possibility to use innovative experimental therapies as therapeutic alternatives, in particular, in patients in whom conventional drugs have failed or have been found to be poorly effective.

This last aspect is achieved thanks to the continuous participation of IOV in clinical trials, both national and international, which involve the use of non-commercialized medicines that are not available on the Italian market. In addition, the Institute’s medical specialists promote, design and carry out clinical trials that explore possible new indications of drugs already on the market, in order to test new therapeutic strategies and thus offer further possibilities of cure.

All clinical trials, whether promoted by the pharmaceutical industry or by non-profit organizations, are conducted at IOV according to strict ethical, regulatory and quality standards. Before being started, each trial must be approved by the Ethics Committee for clinical trials, in accordance with the regulations on clinical trials, the dictates of good clinical practice (GCP) and the ethical principles indicated in the Helsinki Declaration.

For the patients included in the experimental protocols, the main care reference is the research nurses, who represent a flagship of the scientific activity of the IOV, one of only two Italian centers to have this professional figure.

The levels of research, diagnosis and treatment conducted in the Institute place the IOV among the most accredited cancer centers nationwide.

Incidenza di infezione da COVID-19 severa in pazienti con Leucemia Linfatica Cronica o Linfoma non Hodgkin Indolente a cellule B che hanno ricevuto profilassi con Tixagevimab e Cilgavimab in Italia: studio osservazionale condotto dal Working party GIMEMA sulle malattie linfoproliferative croniche e della Fondazione Italiana Linfomi

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
GIMEMA CLL2423
Codice EudraCT
NP
Sponsor/Promotore
FONDAZIONE G.I.M.EM.A (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) ONLUS
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Studio prospettico di fase III in doppio cieco, randomizzato, controllato con placebo, volto a valutare l’efficacia e la sicurezza di Panzyga nella profilassi delle infezioni primarie in pazienti affetti da leucemia linfatica cronica (studio ‘PRO-SID’)

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
NGAM-12 (PRO-SID)
Codice EudraCT
2019-004375-40
Sponsor/Promotore
Octapharma AG
Tipologia
Sperimentale
Fase
III
Unità Operativa
Principal Investigator

Studio ambispettico multicentrico sulle complicanze infettive riscontrate nei pazienti affetti da leucemia linfatica cronica trattati con venetoclax

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
seifem venetoclax in LLC
Codice EudraCT
NP
Sponsor/Promotore
Policlinico Universitario A. Gemelli di Roma
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Search

Status

Qualsiasi
Aperto - reclutamento in corso(3)

Last modified: 06/04/2021 15:13